Background: Development of recalcitrant stenotic lesions of the cephalic arch is a significant cause of dysfunction of brachiocephalic access arteriovenous fistulas (AVFs). Endovascular and surgical therapy can be used to treat cephalic arch stenosis. The aim of this study was to evaluate the outcomes of endovascular and surgical interventions for cephalic arch stenosis.
The prevalence of patients diagnosed with end-stage renal disease and undergoing hemodialysis continues to rise. 1 Implementation of guidelines, such as the Kidney Disease Outcomes Quality Initiative, has succeeded in increasing the use of native arteriovenous fistulas (AVFs) and thus the number of complications reported for these types of access. 2 Dysfunctional AVF represents one of the leading causes of morbidity in the hemodialysis population, with venous stenosis-related dysfunction being the most common underlying problem. 3, 4 Cephalic arch stenosis is seen in up to 77% of dysfunctional brachiocephalic AVFs 5 and in 15% of dysfunctional AVFs overall. 6 Endovascular and surgical therapy can be used to treat cephalic arch stenosis. The purpose of this retrospective study was to evaluate the outcomes of endovascular and surgical interventions for cephalic arch stenosis that has resulted in dysfunctional brachiocephalic AVFs.
METHODS
Study design. This retrospective review of all patients during a 16-year period with a compromised but not occluded brachiocephalic AVF due to cephalic arch stenosis was undertaken from January 2000 to December 2015 at a single institution with six surgeons. The cephalic arch was defined as the terminal portion of the cephalic vein as it joins with the axillary vein to form the subclavian vein. It is the arching part of the cephalic vein as it enters the deltopectoral groove, passes beneath the clavicle, and turns sharply to pierce the clavipectoral fascia. 7 For the purposes of this study, the index stenosis was within 5 cm of the confluence of the cephalic vein with the axillary vein and was >50%. Four cephalic arch intervention groups were identified: angioplasty alone, stenting, bypass, and transposition. Study data were obtained by a review of the patients' medical records as part of an Institutional Review Board-approved protocol. Consent was waived because patients were not directly studied and the data collection was retrospective and deidentified.
Patients. All patients who had a brachiocephalic AVF for hemodialysis access were identified retrospectively by a review of administrative/billing data, operative logs, and patient medical records. Patients with primary surgical creation of a brachiocephalic AVF for hemodialysis access with patent central veins were considered eligible for inclusion. The index stenosis had to be within 5 cm of the confluence of the cephalic vein with the axillary vein. Patients with a radiocephalic AVF, revision of AVF, or prior arteriovenous graft placed in the same extremity were excluded. Only one brachiocephalic AVF for permanent hemodialysis access per patient was included in this review to maintain independence of observations (eg, to avoid the bias of only some patients accounting for the major proportion of access complications or failures); this was the first brachiocephalic AVF presenting for intervention. An index stenosis was a stenosis (>50%) found within the anatomic boundaries describing the cephalic arch; any stenosis involving the axillary vein or >5 cm from the axillocephalic confluence was excluded.
Management. Patients with AVFs were observed by their access centers, and many returned for duplex ultrasound surveillance at 3 or 5 months. The general management strategy was diagnostic fistulography, followed by central venous venography to assess the fistula and to rule out central venous stenosis or occlusion; this was followed by either an endovascular intervention or the use of a surgical intervention for lesions not amenable to or that failed endovascular interventions. Indications for endovascular intervention included identification of high dynamic venous pressures (<300 mm Hg), suboptimal blood flow (<400 mL/min) during hemodialysis, prolonged bleeding time after hemodialysis, abnormal findings on clinical examination (such as weak or absent thrill, pulsatility, ipsilateral arm edema), and access pain during hemodialysis. Angioplasty with or without a cutting balloon was used, and a stent was placed for recalcitrant stenosis, abrupt occlusion, or perforation. Indications for surgical intervention included cephalic arch total occlusion, frequently recurrent stenosis (requiring angioplasty in <3-month intervals), highgrade elastic stenosis (residual stenosis >50% after angioplasty), recurrent in-stent stenosis (requiring intervention in <3-month intervals), and other lesions not amenable to endovascular interventions. Secondary interventions were performed on the basis of clinical and hemodialysis parameters that indicated a failing or failed access. Identification of high dynamic venous pressures (<300 mm Hg) or suboptimal blood flow (<400 mL/min) during hemodialysis was the most frequent indication for intervention, followed by prolonged bleeding time after hemodialysis, abnormal findings on clinical examination (such as weak or absent thrill, pulsatility, ipsilateral arm edema suggestive of central venous stenosis), and access pain during hemodialysis.
Definition of outcomes. Access complications, intervention or access salvage procedures, and access patency were ascertained and reported according to the reporting standards developed by the Society for Vascular Surgery. 8 Statistical analysis. All statistical analyses were performed on an intention-to-treat basis. Data were analyzed using JMP software version 9.0 (SAS Institute, Cary, NC). Kaplan-Meier analysis was used to estimate primary, assisted primary, and secondary patency. Measured values are reported as percentages or mean 6 standard deviation.
RESULTS
Study population. There were 617 brachiocephalic AVFs identified, and 35% had cephalic arch stenosis that matched the inclusion criteria (35%); 219 (67% female; mean age, 58 6 20 years) with a failing brachiocephalic AVF due to cephalic arch stenosis underwent intervention. The average time to intervention for cephalic arch stenosis was 1.7 years after primary access placement. The average number of percutaneous interventions before the decision to intervene surgically on the cephalic arch was three (range, two to six). Demographic data for the four treatment modalities are shown in Table I The authors suggest that surgery should be considered early when cephalic arch stenosis is identified in angioaccess patients.
were significantly younger. Patients undergoing surgery had significantly more percutaneous interventions and had a lower modified Cardiac Risk Index (Table I) . There was no other significant difference in comorbidities between the groups (Table I ). All patients had a high functional capacity as indicated by their ambulatory status (Table I) . There was no difference in statin or antiplatelet administration between the groups. Patients had a median of less than one central line placement before the primary brachiocephalic AVF placement, and 6% had an indwelling hemodialysis catheter at the time of the index procedure.
Procedure. All the percutaneous procedures were performed under conscious sedation. All the patients undergoing transposition or bypass underwent general anesthesia. The majority of the balloon angioplasties were performed with a high-pressure balloon, and 21%
were treated with a cutting balloon. All the stents placed were uncovered self-expanding stents. Technical success was superior in the surgical groups (70% and 80% compared with 96% and 100% for balloon angioplasty, stenting, transposition, and bypass, respectively; P < .05); 67% of the technical failures in the angioplasty group were treated with a self-expanding stent. The conduit for bypass was great saphenous vein in 70% of the cases and expanded polytetrafluoroethylene in the remainder, with the axillary vein being the outflow conduit in 81%, the jugular vein and the subclavian in the remainder. One of the transposition procedures required an anastomotic revision. The rate of major adverse cardiovascular events was overall low but significantly higher in the surgical groups (0.3%, 0.3%, 1%, and 1% for balloon angioplasty, stenting, transposition, and bypass, respectively; P ¼ .04). Mean time to access was immediate in the endovascular group and 1.1 6 0.4 weeks for the surgical group (P ¼ .001). There were more intraprocedural events noted in the endovascular groups (Table II) . Adverse events were categorized into major (requiring surgical or percutaneous interventions) and minor (requiring nonoperative management). Minor complications included suspected graft infection treated by antibiotics and wound healing/skin erosion. The rate of these complications, including events that occurred within 30 days of the index procedure and late events (>30 days after index procedure), was similar between the two treatment groups (Table II) . The occurrence of venous anastomotic disease (ie, at the venous-to-venous anastomosis) was more common in the surgery group.
Follow-up. Median follow-up was 47 months (12-60 months), with 17% of patients lost to follow-up. The 2-year primary, assisted primary, and secondary patency rates were significantly superior in the surgery groups (Fig) . These groups had a lower secondary intervention rate (3.5, 3.1, 1.9, and 1.4 interventions per person-year of follow-up for balloon angioplasty, stenting, transposition, and bypass, respectively; P ¼ .03). Median functional dialysis durations were equivalent between angioplasty (1.9 years) and stenting (2.1 years) groups and between transposition (3.1 years) and bypass (3.4 years) surgical groups. However, both surgical groups were significantly superior to the percutaneous groups (P ¼ .01).
DISCUSSION
In this retrospective study, surgical intervention for cephalic arch stenosis was offered to younger and healthy patients rather than endovascular intervention and resulted in superior patency and functional outcomes. Surgical interventions reduced the number of secondary interventions, and there were no significant differences in long-term complications.
Cephalic arch stenosis is more frequently encountered with brachiocephalic AVFs (39%) compared with radiocephalic AVFs (2%). 6 The incidence of cephalic arch stenosis in this study was similar for brachiocephalic AVFs. Cephalic arch stenotic lesions are generally short and focal in nature and are associated with a high rate of thrombosis. 5 Patients with diabetes have been reported to have a lower rate of cephalic arch stenosis than those without diabetes. 5 Significant wall thickening has been identified in 20% of cephalic veins in patients with renal failure. 9 In addition to these issues, three hemodynamic-related causes have been identified that can increase turbulent flow in the cephalic arch and potentially induce cephalic arch stenosis. The first is the finding that higher flows are seen in brachiocephalic AVFs compared with radiocephalic AVFs. The difference between the two types of AVFs likely results from the fact that the flow in radiocephalic AVFs is distributed between multiple outflow tracts: the cephalic, median antecubital, and basilic systems. 10 The second cause is the tight anatomic cephalic arch angle that can result in elevated shear stress and turbulent flow when the AVF is placed. 11 Finally, the third cause is valvular, with 96% of people having at least one valve within 3 mm of the cephalic arch confluence with the axillary vein. 12, 13 In multivariate analysis of patients with and without cephalic arch stenosis, Jaberi et al 10 reported that renovascular disease, calcium-phosphate product, platelet count, and access flow (per 100 mL/min)*brachiocephalic fistula was predictive of the occurrence of cephalic arch stenosis. Miller et al 14 demonstrated that flow reduction of a brachiocephalic AVF by w42% can effectively diminish the incidence of symptomatic cephalic arch stenosis, which would add credence to a hemodynamic etiology for the development of cephalic arch stenosis. Standard balloon angioplasty with either a normal or a high-pressure balloon remains the first-line management for cephalic arch stenosis. In lesions with rapid recurrence, cutting balloon angioplasty and stent insertion have been used as second-line treatments to improve the duration of the intervention. The value of stenting has not been shown to date. In this study, we saw patencies for both angioplasty and primary stent placement similar to those reported by other authors. In a retrospective 48-month review, Rajan et al 6 reported primary and secondary patencies of 23% and 75% at 12 months, respectively, after simple balloon angioplasty. When a cutting balloon angioplasty was used in a second study by Heerwagen et al, 15 there was no appreciable difference in patency, but there was a lower secondary intervention rate for cutting compared with standard balloon angioplasty (0.9 vs 2.2 interventions per person-year of followup). Whereas bare-metal stents have not been directly compared with balloon angioplasty in the cephalic arch, most reports on bare-metal stents show no benefit over angioplasty in the cephalic arch. 6, 16 One report has suggested a benefit of bare-metal stent placement over angioplasty alone. 17 In a study of 11 patients, the use of a covered stent to treat cephalic arch stenosis (6 for residual stenosis and 5 for rupture) resulted in a primary patency rate of 73% at 12 months and a secondary patency rate of 91% at 6 months. 16 In a prospective randomized clinical trial of bare-metal stents compared with covered stents for cephalic arch stenosis, Shemesh et reported that restenosis rates were significantly higher (P ¼ .024) in the bare stent group (70%) compared with the stent graft group (18%) within 3 months of the index interventions. 18 These authors also reported a significant , and the data set terminates if the number at risk is <10. There was no difference between two surgical therapies or endovascular therapies. The numbers on the right side of the figure reflect the value of either the combined open or the combined endovascular groups with a P value derived by log-rank sum testing.
difference (P ¼ .0023) in 1-year primary patency of 32% in the stent graft group and 0% in the bare stent group. No covered stents were used in this study. Surgical intervention, whether by patch angioplasty, transposition, or bypass, has been reported as a means of treating cephalic arch stenosis after AVF placement. We did not perform any patch angioplasties. Bypasses to the axillary, jugular, and subclavian veins have been reported to be viable options in the presence of outflow stenosis, but there are few large cohort reports published. [19] [20] [21] In this study, both transposition and bypass achieved higher patencies than endovascular interventions, and these findings are supported by other reports in the literature. that angioplasty of the proximal cephalic vein before transposition was the only significant predictor of the lower primary patency rate for the surgical intervention.
In a meta-analysis of therapy for cephalic arch stenosis, Vasanthamohan et al 26 concluded that no single, definitive management strategy exists for cephalic arch stenosis and that current studies are limited by being primarily single-center retrospective trials featuring heterogeneous populations of patients, interventions, and end points. As a retrospective study, this study suffers from many of the limitations of a retrospective study with a small number in each group, a heterogeneous population, and a multicenter experience. In general, patients chosen for surgery were younger and had a lower cardiac risk and fewer comorbidities, reflecting the surgeon's bias as to who should be offered open intervention, and this could have influenced the positive results reported.
CONCLUSIONS
Cephalic arch stenosis is a significant cause of brachiocephalic AVF malfunction. Surgical options offer superior long-term patency and functional results and should be considered earlier in the treatment of this disease. 
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